Federated Hermes Inc. Has $3.47 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Posted by on Mar 10th, 2023

Federated Hermes Inc. lifted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 7.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,042 shares of the biopharmaceutical company’s stock after purchasing an additional 371 shares during the quarter. Federated Hermes Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,473,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in Regeneron Pharmaceuticals by 92.5% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,694,308 shares of the biopharmaceutical company’s stock worth $1,001,556,000 after buying an additional 813,967 shares during the last quarter. Renaissance Technologies LLC raised its holdings in shares of Regeneron Pharmaceuticals by 108.3% in the 2nd quarter. Renaissance Technologies LLC now owns 583,062 shares of the biopharmaceutical company’s stock worth $344,665,000 after acquiring an additional 303,200 shares during the last quarter. Massachusetts Financial Services Co. MA acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $136,678,000. FMR LLC lifted its position in Regeneron Pharmaceuticals by 1.9% in the 2nd quarter. FMR LLC now owns 10,176,199 shares of the biopharmaceutical company’s stock valued at $6,015,457,000 after acquiring an additional 193,175 shares in the last quarter. Finally, Great West Life Assurance Co. Can acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $116,414,000. 84.25% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $762.50, for a total transaction of $76,250.00. Following the completion of the sale, the director now owns 19,147 shares of the company’s stock, valued at $14,599,587.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $762.50, for a total value of $76,250.00. Following the transaction, the director now directly owns 19,147 shares in the company, valued at $14,599,587.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction that occurred on Wednesday, March 1st. The stock was sold at an average price of $759.89, for a total transaction of $835,879.00. Following the completion of the transaction, the executive vice president now directly owns 20,803 shares of the company’s stock, valued at approximately $15,807,991.67. The disclosure for this sale can be found here. Insiders sold 27,537 shares of company stock worth $21,382,744 in the last three months. Corporate insiders own 8.99% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $743.75 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.29 and a current ratio of 5.06. The stock has a market capitalization of $81.31 billion, a price-to-earnings ratio of 19.45, a price-to-earnings-growth ratio of 2.56 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $800.48. The stock’s 50-day simple moving average is $743.18 and its 200 day simple moving average is $722.31.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last announced its quarterly earnings results on Friday, February 3rd. The biopharmaceutical company reported $12.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $8.18 by $4.38. The firm had revenue of $3.41 billion for the quarter, compared to the consensus estimate of $3.11 billion. Regeneron Pharmaceuticals had a net margin of 35.64% and a return on equity of 22.87%. The company’s revenue for the quarter was down 31.1% on a year-over-year basis. During the same period in the prior year, the firm posted $23.72 earnings per share. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. SVB Leerink raised their target price on Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the company a “market perform” rating in a report on Monday, February 6th. Wells Fargo & Company lifted their price objective on shares of Regeneron Pharmaceuticals from $800.00 to $860.00 and gave the stock an “overweight” rating in a report on Friday, February 17th. Royal Bank of Canada increased their target price on shares of Regeneron Pharmaceuticals from $787.00 to $806.00 and gave the company a “sector perform” rating in a report on Thursday. Cowen upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price target for the stock from $775.00 to $875.00 in a report on Monday, January 30th. Finally, Guggenheim decreased their price objective on shares of Regeneron Pharmaceuticals from $925.00 to $915.00 and set a “buy” rating for the company in a research note on Friday, November 11th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $804.10.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Featured Articles

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.